Drug side effects
hydromorphone Side Effects
The reactions most often reported to the FDA for hydromorphone (also sold as Dilaudid), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 90,652
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2002 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of hydromorphone come from 90,652 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 90,652 reports to the FDA Adverse Event Reporting System (FAERS) for hydromorphone (Dilaudid): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
90,652
Reports Mentioning Death
27,836
30.7% of reports — not proof the medicine caused the death
Hospitalizations
16,698
18.4% of reports
Top Indication
Pain
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 27,836 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 14,855 |
| TOXICITY TO VARIOUS AGENTS | 8,391 |
| OVERDOSE | 8,150 |
| DRUG DEPENDENCE | 3,639 |
| DRUG ABUSE | 1,572 |
| PAIN | 879 |
| ACCIDENTAL OVERDOSE | 745 |
| NAUSEA | 737 |
| FATIGUE | 660 |
| DRUG WITHDRAWAL SYNDROME | 642 |
| VOMITING | 578 |
| INTENTIONAL PRODUCT MISUSE | 562 |
| SEPSIS | 542 |
| DYSPNOEA | 540 |
| PNEUMONIA | 511 |
| ABDOMINAL PAIN | 489 |
| ASTHENIA | 477 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 451 |
| PYREXIA | 450 |
Reactions in Hospitalization Reports
Top reactions in 16,698 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PAIN | 2,423 |
| NAUSEA | 2,248 |
| DRUG DEPENDENCE | 1,856 |
| TOXICITY TO VARIOUS AGENTS | 1,649 |
| VOMITING | 1,521 |
| FATIGUE | 1,445 |
| ABDOMINAL PAIN | 1,434 |
| PYREXIA | 1,330 |
| OVERDOSE | 1,324 |
| DYSPNOEA | 1,249 |
| DIARRHOEA | 1,206 |
| PNEUMONIA | 1,204 |
| HEADACHE | 1,159 |
| MALAISE | 1,086 |
| WEIGHT DECREASED | 1,037 |
| FALL | 999 |
| ANXIETY | 992 |
| ASTHENIA | 967 |
Nearby, Related Medications
What the FAERS Data Reveals About hydromorphone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 90,652 voluntary reports linked to hydromorphone and its brand equivalents (Dilaudid), spanning 2002 through 2025. Of those, 27,836 (30.7%) listed death as an outcome and 16,698 (18.4%) involved hospitalization. The most common indication reported alongside adverse events was Pain.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 52% were female and 48% male; age distribution skews toward 45-64, with 9,773 reports in that bracket. The single most reported reaction is drug dependence with 35,077 submissions, followed by overdose and pain.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to hydromorphone's 90,652.
Read our methodology - how this data is sourced, computed, and verified.